Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?

Drug metabolism and disposition: the biological fate of chemicals - 1 Nov 2005

Rodrigues A David

Abstract excerpt

The market withdrawals of rofecoxib (Vioxx) and valdecoxib (Bextra) have focused considerable attention on the side effect profiles of cyclooxygenase (COX) inhibitors. As a result, attempts will be made to identify risk factors in the hope that physicians might be able to ensure patient safety. At first glance, CYP2C9 genotype might be considered a risk factor because many COX inhibitors are CYP2C9 substrates in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cardiovascular System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclooxygenase 2 Inhibitors

Share to Cyclooxygenase Inhibitors

Share to Cytochrome P-450 CYP2C8

Share to Cytochrome P-450 CYP2C9

Share to Cytochrome P-450 CYP3A

Share to Gastrointestinal Tract

Source

Identifiers

PMID: 16118328
DOI: 10.1124/dmd.105.006452

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?PMID 16118328Read ↗

Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.Semantic proximity Read ↗

Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?Semantic proximity Read ↗

The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendationsSemantic proximity Read ↗

Clinical consequences of cytochrome P450 2C9 polymorphisms.Semantic proximity Read ↗

[Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs].Semantic proximity Read ↗

Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite.Semantic proximity Read ↗

Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects.Semantic proximity Read ↗

How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity.Semantic proximity Read ↗

Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.Semantic proximity Read ↗

Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.Semantic proximity Read ↗

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.Semantic proximity Read ↗

The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.